Red cell survival in relation to changes in the hematocrit: More important than you think

Blood Purification

Volumn 26, Issue 4, 2008, Pages 355-360

  Kalicki, Robert M ^a   Uehlinger, Dominik E ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chronic renal failure; Dialysis; Dosing algorithm; Erythrocyte lifespan; Erythrocyte survival function; Erythropoietin

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CELL ACTIVITY; CHRONIC KIDNEY FAILURE; DECISION SUPPORT SYSTEM; DOSE RESPONSE; DRUG EFFECT; ERYTHROCYTE; ERYTHROCYTE COUNT; ERYTHROCYTE LIFESPAN; ERYTHROPOIESIS; HEMATOCRIT; HUMAN; PRIORITY JOURNAL; STEM CELL;

ALGORITHMS; ANEMIA; CELL SURVIVAL; DECISION MAKING, COMPUTER-ASSISTED; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTES; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATOCRIT; HUMANS; KIDNEY FAILURE, CHRONIC;

EID: 48349109536     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000133838     Document Type: Article

References (30)

1. Clase CM, Kiberd BA, Garg AX: Relationship between glomerular filtration rate and the prevalence of metabolic abnormalities: results from the Third National Health and Nutrition Examination Survey (NHANES III). Nephron Clin Pract 2007;105:c178-c184.
2. Benz RL, Pressman MR, Hovick ET, Peterson DD: Potential novel predictors of mortality in end-stage renal disease patients with sleep disorders. Am J Kidney Dis 2000;35:1052-1060.
3. Levin A, Thompson CR, Ethier J, et al: Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999;34:125-134.
4. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999;10:610-619.
5. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ: Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 2000;15:1425-1430.
6. Nissenson AR: Epoetin and cognitive function. Am J Kidney Dis 1992;20:21-24.
7. Remuzzi G, Ingelfinger JR: Correction of anemia - payoffs and problems. N Engl J Med 2006;355:2144-2146.
8. Pelufo PA, Monte BE, Poveda Andres JL, Cuellar Monreal MJ: A descriptive study of erythropoietin use and cost in hematologic patients. Farm Hosp 2006;30:343-350.
9. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther 2003;306:324-331.
10. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 2004;44:991-1002.
11. Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992;51:76-89.
12. Woo S, Krzyzanski W, Jusko WJ: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats. J Pharmacol Exp Ther 2006;319:1297-1306.
13. Locatelli F, Aljama P, Barany P, et al: Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19(suppl 2):ii1-ii47.
14. Locatelli F, Pisoni RL, Akizawa T, et al: Anemia management for hemodialysis patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) findings. Am J Kidney Dis 2004;44:27-33.
15. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339:584-590.
16. Regidor DL, Kopple JD, Kovesdy CP, et al: Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol 2006;17:1181-1191.
17. Singh AK, Szczech L, Tang KL, et al: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085-2098.
18. Krzyzanski W, Jusko WJ: Mathematical formalism for the properties of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1997;25:107-123.
19. Krzyzanski W, Ramakrishnan R, Jusko WJ: Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm 1999;27:467-489.
20. Krzyzanski W, Jusko WJ, Wacholtz MC, Minton N, Cheung WK: Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 2005;26:295-306.
21. Krzyzanski W, Perez-Ruixo JJ: An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res 2007;24:758-772.
22. Perez-Ruixo JJ, Kimko HC, Chow AT, Piotrovsky V, Krzyzanski W, Jusko WJ: Population cell life span models for effects of drugs following indirect mechanisms of action. J Pharmacokinet Pharmacodyn 2005;32:767-793.
23. Woo S, Jusko WJ: Interspecies comparisons of pharmacokinetics and pharmacodynamics of recombinant human erythropoietin (rHuEPO). Drug Metab Dispos 2007;35:1672-1678.
24. Capelli JP, Kushner H: Developing an algorithm to convert erythropoietin dosing to darbepoetin alfa. Nephrol News Issues 2006;20:33, 35, 39.
25. Icardi A, Sacco P, Salvatore F, Romano U: Long-term intravenous epoetin-alpha/darbepoetin-alpha ratio in iron-replete hemodialysis patients. J Nephrol 2007;20:73-79.
26. Eadie GS: Studies of red cell survival. Ann NY Acad Sci 1959;77:737-752.
27. Balestri PL, Cioni L, Giovannetti S: Spontaneous autohemolysis due to incubation in chronic uremic patients. Minerva Nefrol 1965;12:125-128.
28. Tolman C, Richardson D, Bartlett C, Will E: Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: a randomized clinical study. J Am Soc Nephrol 2005;16:1463-1470.
29. Will EJ, Richardson D, Tolman C, Bartlett C: Development and exploitation of a clinical decision support system for the management of renal anaemia. Nephrol Dial Transplant 2007;22(suppl 4):iv31-iv36.
30. Gabutti L, Lotscher N, Bianda J, Marone C, Mombelli G, Burnier M: Would artificial neural networks implemented in clinical wards help nephrologists in predicting epoetin responsiveness? BMC Nephrol 2006;7:13.